Skip to content
Screener

Replimune Group REPL Debt-to-equity

Debt-to-equity at other companies

Amgen logo
AmgenAMGN
4.9×-2.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
-0.1×
Regenxbio logo
RegenxbioRGNX
+0.6×
Immunome logo
ImmunomeIMNM
0.0×
CG Oncology logo
CG OncologyCGON
0.0×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on the most recent quarter.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026. Open the filing →

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805

FAQ

What is Replimune Group's debt-to-equity?
Replimune Group (REPL) reported debt-to-equity of 0.4× in Q4 2025.
How has Replimune Group's debt-to-equity changed year-over-year?
Replimune Group's debt-to-equity increased by 130.2% year-over-year, from 0.2× to 0.4×.
What is the long-term trend for Replimune Group's debt-to-equity?
Over 4 years (2021 to 2025), Replimune Group's debt-to-equity has grown at a 27.6% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Replimune Group's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude